KẾT QUẢ ĐIỀU TRỊ DUY TRÌ UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV BẰNG VINORELBINE ĐƯỜNG UỐNG TẠI BỆNH VIỆN K

Abstract

Objective: To evaluate the outcomes of maintenance switch therapy with oral Vinorelbine and the associated adverse events in patients with stage IV non-small cell lung cancer (NSCLC). Methods: A descriptive study was conducted on 55 patients with stage IV NSCLC who had not progressed after first-line chemotherapy with a platinum-based doublet regimen. These patients received maintenance switch therapy with oral Vinorelbine at Vietnam National Cancer Hospital from March 2023 to June 2024. Results: The mean age of the patients was 61.2 ± 8.77 years; 81.8% were male and 18.2% were female. All patients had a performance status (PS) of 0-1, with 36.4% having a PS of 0 and 63.6% having a PS of 1. The overall response rate was 12.7%, and the disease control rate was 65.5%. No statistically significant differences in response rates were observed concerning gender, PS, or smoking history. The median progression-free survival (PFS) was 5.1 months (95% confidence interval (CI), 3.4-9.2 months). Common adverse events included leukopenia (20%, mostly grade 1), neutropenia (21.8%, with 9.1% being grade 3), and hemoglobin reduction (41.8%, mostly grade 1). Other toxicities were less frequent. Conclusion: The study demonstrates that maintenance therapy with oral Vinorelbine is effective in controlling disease progression in stage IV NSCLC patients, with manageable toxic effects.